News Release

Two-faced protein both inhibits and activates B cell receptor signaling

Peer-Reviewed Publication

Tokyo Medical and Dental University

CD22-mediated Functional restoration of immunodeficient B cells mediated by CD22 interaction with its ligand

image: When antigens interact with the antigen receptor on B cells, B cells undergo activation and differentiation to antibody-producing cells (plasma cells). Defects in signaling through the antigen receptor cause immunodeficiency. In this study, the authors showed that the function of immunodeficient B cells is restored by increasing the amount of antigen receptors during development of mature B cells. This process requires interaction of CD22 with its cis-ligands. view more 

Credit: Department of Immunology,TMDU

Researchers from TMDU find that CD22 restores B cell function in B cell receptor (BCR) signaling deficiencies by interacting with cis-ligands and upregulating BCR expression, thereby paradoxically augmenting BCR signaling

Tokyo, Japan - The rules to the kids’ game “red light, green light” are easy to follow: red always means stop, and green always means go. But now, researchers from Japan have found that a key protein involved in B cell signaling acts as both a red light to signaling in healthy cells and a green light to signaling in immune-deficient cells.

In a study published in March in Science Signaling, researchers from Tokyo Medical and Dental University (TMDU) have revealed that CD22, a crucial molecule in B cell signaling, switches from an inhibitory role to an activating role when B cell receptor (BCR) signaling is compromised due to a genetic defect that causes an immune disorder.

Contact between BCRs and foreign invaders prompts B cells to make antibodies, and CD22 inhibits BCR signaling to keep B cells from inappropriately releasing antibodies. Interestingly, previous research suggests that this inhibition is regulated by binding of CD22 to other factors expressed on the same cell. In contrast, a protein called CD45 is a main activator of BCR signaling, and defects in the gene encoding CD45 cause an immunodeficiency syndrome.

“CD45 normally enhances BCR signaling,” explains Chizuru Akatsu, lead author on the study. “When CD45 is missing in laboratory cell lines, BCR signaling is dramatically decreased; however, signaling is not affected as severely in mice when CD45 is missing, which suggests that there is some kind of compensatory mechanism at work.”

To investigate the relationship between CD22 and BCR signaling restoration in the absence of CD45, the researchers disrupted the binding of all interaction partners of CD22 either continuously or for a short time and looked at the effect this had on BCR signaling.

“The results were entirely unexpected,” says Takeshi Tsubata, senior author. “Acute disruption of binding between CD22 and its ligands did not affect the restoration of BCR signaling in B cells lacking CD45, whereas continuous disruption of this binding resulted in markedly less BCR signaling recovery.”

As it turns out, the cells in which signaling was restored expressed unusually high levels of BCR, which accounted for their ability to continue functioning relatively normally. BCR signaling occurs at low levels even in the absence of stimulation by foreign antigens, and this low-level steady-state signaling is required for B cell development and survival. Because BCR is an endogenous ligand of CD22, continuous CD22 binding to its ligands facilitates inhibition of steady-state BCR signaling by CD22. If BCR signaling is compromised by a defect such as CD45 deficiency, steady-state signaling is markedly reduced by the signaling defect together with the signal inhibition by CD22; therefore, only B cells that express high levels of BCR survive. Through this mechanism, CD22 paradoxically restores BCR signaling in immune-deficient B cells.

“What is really interesting about this result is that it could point toward a way to restore immune function in patients with immune disorders involving B cell signaling deficiencies,” states Akatsu.

Given that B cells and immunoglobulins are present — though in greatly reduced numbers — in immunodeficient patients with defects in BCR signaling, CD22 may be a useful treatment target. Activating CD22 could help restore B cell function in patients with B cell signaling deficiencies such as X-linked agammaglobulinemia.


The article, “The inhibitory coreceptor CD22 restores B cell signaling by developmentally regulating Cd45−/− immunodeficient B cells,” was published in Science Signaling at DOI: 10.1126/scisignal.abf9570.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.